Compare INDI & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDI | ASMB |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.9M | 553.6M |
| IPO Year | N/A | 2010 |
| Metric | INDI | ASMB |
|---|---|---|
| Price | $4.41 | $35.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $6.25 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 3.4M | 134.1K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $217,396,000.00 | $37,191,000.00 |
| Revenue This Year | $1.91 | $42.01 |
| Revenue Next Year | $30.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.30 |
| 52 Week Low | $1.53 | $7.75 |
| 52 Week High | $6.05 | $39.71 |
| Indicator | INDI | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 55.32 | 57.21 |
| Support Level | $3.44 | $34.42 |
| Resistance Level | $4.76 | $38.82 |
| Average True Range (ATR) | 0.27 | 2.11 |
| MACD | 0.14 | -0.41 |
| Stochastic Oscillator | 78.26 | 40.31 |
Indie Semiconductor Inc is empowering the Autotech revolution with next-generation automotive semiconductors and software platforms. It focuses on edge sensors for Driver Assistance Systems including LiDAR, connected car, user experience, and electrification applications. These technologies represent the core underpinnings of both electric and autonomous vehicles, while the user interfaces transform the in-cabin experience to mirror and seamlessly connect to the mobile platforms. Geographically, the company generates majority of its revenue from Greater China and rest from United States, Europe, South Korea and other regions.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.